Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Arix Bioscience stock price, quote, forecast and news

ARIX.L
GB00BD045071
A2DL9L

Price

1.42
Today +/-
+0
Today %
+0 %
P

Arix Bioscience Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Arix Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Arix Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Arix Bioscience’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Arix Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Arix Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Arix Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Arix Bioscience’s growth potential.

Arix Bioscience Revenue, EBIT and net profit per share

DateArix Bioscience RevenueArix Bioscience EBITArix Bioscience Net Income
2025e0 undefined0 undefined0 undefined
2024e0 undefined-15.14 M undefined0 undefined
2023e0 undefined-9.37 M undefined24.59 B undefined
2022112,000 undefined-5.29 M undefined-27.58 M undefined
2021340,000 undefined-4.73 M undefined-61.08 M undefined
2020480,000 undefined-7.28 M undefined126.3 M undefined
2019510,000 undefined-9.2 M undefined-69.69 M undefined
20181.33 M undefined-10.37 M undefined36.88 M undefined
20171.86 M undefined-9.13 M undefined-7.47 M undefined
2016640,000 undefined-9.66 M undefined-8.84 M undefined
20150 undefined-2.21 M undefined-4.2 M undefined

Arix Bioscience Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (k)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201520162017201820192020202120222023e2024e2025e
001,0001,0000000000
-----------
-----------
0000000-30000
-2-9-9-10-9-7-4-5-9-150
---900.00-1,000.00-------
-0-0.01-0.010.04-0.070.13-0.06-0.0324.5900
-100.00-12.50-614.29-291.67-282.61-148.41-55.74-91,166.67--
90.1290.1278.73128.52129.95142.34126.95124.1000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Arix Bioscience Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Arix Bioscience is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Arix Bioscience provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Arix Bioscience's financial health and stability.

Assets

Arix Bioscience's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Arix Bioscience must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Arix Bioscience after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Arix Bioscience's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2015null2016201720182019202020212022
-4-4-9-742-75126-61-27
000000000
000000000
0020-100-10
110-1-5367-1335522
000000000
000000000
-2-2-7-8-11-8-6-7-4
000000000
-5-5-13-50-115346642-12
-5-5-12-50-115346642-12
000000000
000000000
5050501058200-110
4848501058200-110
-2.00-2.00-------
000000000
40402846-43235722-11
-2.310-8.35-8.79-11.06-8.48-6.74-7.24-4.64
000000000

Arix Bioscience stock margins

The Arix Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arix Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arix Bioscience.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Arix Bioscience's sales revenue. A higher gross margin percentage indicates that the Arix Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Arix Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Arix Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Arix Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Arix Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Arix Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Arix Bioscience Margin History

Arix Bioscience Gross marginArix Bioscience Profit marginArix Bioscience EBIT marginArix Bioscience Profit margin
2025e-27,375 %0 %0 %
2024e-27,375 %0 %0 %
2023e-27,375 %0 %0 %
2022-27,375 %-4,725.89 %-24,620.54 %
2021-27,375 %-1,391.18 %-17,964.71 %
2020-27,375 %-1,516.67 %26,312.5 %
2019-27,375 %-1,803.92 %-13,664.71 %
2018-27,375 %-779.7 %2,772.93 %
2017-27,375 %-490.86 %-401.61 %
2016-27,375 %-1,509.38 %-1,381.25 %
2015-27,375 %0 %0 %

Arix Bioscience Stock Sales Revenue, EBIT, Earnings per Share

The Arix Bioscience earnings per share therefore indicates how much revenue Arix Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arix Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arix Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arix Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arix Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Arix Bioscience Revenue, EBIT and net profit per share

DateArix Bioscience Sales per ShareArix Bioscience EBIT per shareArix Bioscience Earnings per Share
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
2023e0 undefined0 undefined190.04 undefined
20220 undefined-0.04 undefined-0.22 undefined
20210 undefined-0.04 undefined-0.48 undefined
20200 undefined-0.05 undefined0.89 undefined
20190 undefined-0.07 undefined-0.54 undefined
20180.01 undefined-0.08 undefined0.29 undefined
20170.02 undefined-0.12 undefined-0.09 undefined
20160.01 undefined-0.11 undefined-0.1 undefined
20150 undefined-0.02 undefined-0.05 undefined

Arix Bioscience business model

Arix Bioscience PLC is a leading investment and management provider in the biotech industry. The company is focused on identifying, investing in, and growing emerging companies to develop groundbreaking therapies for patients worldwide. The firm was founded in 2016 in London, United Kingdom, and has since focused on collaborating with emerging biotech companies. Arix is now one of the fastest-growing biotech companies in the region, with locations in London, New York, and Zug, Switzerland. Arix Bioscience's business model is based on investing in young biotechnology companies and supporting their growth. The goal is to develop new drugs and therapies by driving innovation in the biotech industry, ultimately benefiting patients worldwide, including those with rare or incurable diseases. To achieve these goals, Arix Bioscience operates in three divisions: Investment, Management, and Discovery. The Investment division actively invests in young biotech companies that aim to develop and commercialize groundbreaking therapies and new diagnostic methods. The company not only provides financial resources but also has extensive experience in the biotech industry and a variety of contacts to offer advisory support when needed. The Management division focuses on effectively managing investments in young biotech companies to fully unleash their growth potential. Arix Bioscience assists these companies, for example, in finding suitable candidates for leadership positions, planning clinical trials, or exploring new markets. The Discovery division specifically targets the discovery and development of new therapies and medications. The company works directly with biotech startups to create a comprehensive value chain that spans from the discovery and exploration of drug molecules to clinical validation. To achieve these goals, Arix Bioscience collaborates closely with leading biotech startups and research institutions worldwide. The company has extensive relationships and networks in the biotech industry, allowing it to optimize the support it provides to its portfolios. Among the products provided by Arix Bioscience is a portfolio of drugs and therapies developed by the biotech companies in which Arix has invested. These portfolios include successful products such as the CD19 CAR-T therapy developed by Autolus Therapeutics, which is used in cancer treatment. Another example is MiroBio, a company in which Arix Bioscience has invested to develop a new medication for autoimmune diseases. Here too, Arix Bioscience has utilized its investment and management expertise to successfully support the company's growth. Overall, Arix Bioscience is a company with a clear focus on innovation and growth in the biotech industry. The company actively invests in emerging biotech startups and provides targeted management and comprehensive support to lead them to great successes. With its extensive experience, Arix Bioscience has become an important player in the development of new therapies and medications. Arix Bioscience is one of the most popular companies on Eulerpool.com.

Arix Bioscience SWOT Analysis

Strengths

Arix Bioscience PLC has several strengths that contribute to its success:

  • Strong research and development capabilities enable the company to innovate and stay ahead of competitors.
  • Established partnerships with leading universities and research institutions provide access to groundbreaking discoveries and cutting-edge technologies.
  • Diverse portfolio of investments in biotech companies reduces potential risks and offers opportunities for growth.
  • Experienced and knowledgeable management team with a proven track record in the biotech industry.

Weaknesses

Despite its strengths, Arix Bioscience PLC faces certain weaknesses that may hinder its performance:

  • Dependence on external collaborations and partnerships for research and development projects increases the risk of delays or setbacks.
  • Reliance on the success of its invested biotech companies exposes Arix Bioscience PLC to potential financial losses if any of those companies underperform.
  • Limited geographical presence restricts market opportunities and potential customer base.

Opportunities

Arix Bioscience PLC can leverage the following opportunities to support its growth:

  • Expanding global demand for innovative biotech solutions offers potential for increased revenues and market expansion.
  • Emerging technologies, such as gene editing and precision medicine, present significant opportunities for Arix Bioscience PLC to invest in and benefit from.
  • Growing partnerships with pharmaceutical companies provide avenues for collaborative research and development projects.

Threats

Arix Bioscience PLC faces several threats that could impact its success:

  • Intense competition in the biotech industry may limit the company's market share and profitability.
  • Uncertainties and regulatory challenges related to drug approval processes create potential obstacles for Arix Bioscience PLC and its invested companies.
  • Economic downturns and changes in healthcare policies could affect funding and investment opportunities in the biotech sector.

Arix Bioscience historical P/E ratio, EBIT, and P/S ratio.

Arix Bioscience shares outstanding

The number of shares was Arix Bioscience in 2023 — This indicates how many shares 124.1 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arix Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arix Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arix Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arix Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Arix Bioscience.

Arix Bioscience latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20190 0  (-87.5 %)2019 Q2
12/31/2018-0 0  (200 %)2018 Q4
6/30/20180.01 0  (-78.22 %)2018 Q2
12/31/2017-0.03 0.03  (185.15 %)2017 Q4
1

Eulerpool ESG Scorecard© for the Arix Bioscience stock

Eulerpool World ESG Rating (EESG©)

17/ 100

🌱 Environment

0

👫 Social

21

🏛️ Governance

31

Environment

Scope 1 - Direct Emissions
3.68
Scope 2 - Indirect emissions from purchased energy
4.41
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
8.09
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Arix Bioscience list of shareholders

%
Name
Stocks
Change
Date
8.74 % Fosun International Holdings, Ltd.11,309,84905/5/2023
5.30 % Chipperton (Christopher)6,862,88905/5/2023
5.15 % Ipsen Pharma SAS6,666,66605/5/2023
4.98 % Ruffer LLP6,440,000-375,0007/14/2023
4.36 % UCB Ventures SA5,647,67905/5/2023
3.48 % TFG Asset Management UK LLP4,500,00005/5/2023
25.52 % RTW Investments L.P.33,023,21033,023,2101/22/2024
1.88 % Link Fund Solutions, Ltd.2,437,67407/31/2023
0.56 % Moncreiffe (Peregrine)719,000100,00011/3/2023
0.39 % Evans (Christopher Thomas)508,058508,0581/1/2023
1
2
3
4

Arix Bioscience Executives and Management Board

Mr. Robert Lyne
Arix Bioscience Chief Executive Officer, Director
Compensation 701,000
Mr. Peregrine Moncreiffe72
Arix Bioscience Non-Executive Independent Chairman of the Board
Compensation 150,000
Dr. Debra Barker61
Arix Bioscience Senior Independent Non-Executive Director
Compensation 38,000
Mr. Andrew Smith61
Arix Bioscience Non-Executive Independent Director
Compensation 33,000
1

Arix Bioscience Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Fosun International Stock
Fosun International
SupplierCustomer0,680,640,350,500,910,74
ReNeuron Group Stock
ReNeuron Group
SupplierCustomer0,67-0,18-0,310,750,790,30
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer0,50-0,08-0,63-0,610,570,04
Acacia Research Stock
Acacia Research
SupplierCustomer0,490,34-0,590,530,790,65
Ipsen Stock
Ipsen
SupplierCustomer-0,34--0,28-0,56-0,50-0,46
Pyxis Oncology Stock
Pyxis Oncology
SupplierCustomer-0,500,020,630,83--
Imara Stock
Imara
SupplierCustomer-0,55-0,260,370,780,93-0,25
1

Most common questions regarding Arix Bioscience

What values and corporate philosophy does Arix Bioscience represent?

Arix Bioscience PLC represents a commitment to innovation, scientific excellence, and long-term value creation. As a leading biotech investment company, Arix focuses on partnering with exceptional life science entrepreneurs and businesses to advance breakthrough therapies and technologies. Arix is dedicated to supporting companies with exciting potential, fostering collaborations, and driving growth within the biotech industry. By leveraging its vast network, expertise, and investment capital, Arix Bioscience PLC seeks to maximize its impact in improving global health while delivering strong returns for its shareholders. Arix's corporate philosophy revolves around identifying and nurturing bold ideas that have the potential to transform patient outcomes and shape the future of medicine.

In which countries and regions is Arix Bioscience primarily present?

Arix Bioscience PLC is primarily present in multiple countries and regions across the globe. The company has a strong global footprint, with its main presence in the United Kingdom, Europe, and North America. Arix Bioscience PLC actively engages in investments and partnerships within these regions to fuel its growth and innovation in the biotech sector. As an internationally recognized biotech company, Arix Bioscience PLC has established a notable presence in key life sciences hubs, including London, New York, and various European cities, enabling it to capitalize on potential investment opportunities and valuable cross-border collaborations.

What significant milestones has the company Arix Bioscience achieved?

Arix Bioscience PLC has achieved several significant milestones. The company successfully raised £100 million during its IPO in 2017 to support its mission. Since then, it has made notable investments in innovative life science companies, fostering growth and advancing breakthrough technologies in the healthcare sector. Arix Bioscience PLC has established strategic partnerships with renowned organizations, collaborating on research and development initiatives. With a dedicated team of experienced professionals, the company continues to drive progress in the biotechnology industry, aiming to improve patient outcomes and revolutionize healthcare. Arix Bioscience PLC's commitment to innovation and strategic investments positions it as a leading player in the life sciences field.

What is the history and background of the company Arix Bioscience?

Arix Bioscience PLC is a renowned biotechnology investment company with a rich history and noteworthy background. Founded in 2016, Arix Bioscience PLC focuses on identifying and supporting medical innovations that have the potential to transform patients' lives. The company collaborates with leading academic institutions, research organizations, and biotech companies to provide capital and expertise in the development of breakthrough therapies. Arix Bioscience PLC emphasizes long-term value creation by investing in promising life science ventures across various therapeutic areas. With a strong track record, Arix Bioscience PLC continues to foster advancements in the biotech industry, consistently driving innovation and delivering potential returns to its shareholders.

Who are the main competitors of Arix Bioscience in the market?

The main competitors of Arix Bioscience PLC in the market include other biotechnology companies such as Vertex Pharmaceuticals, Moderna Therapeutics, Gilead Sciences, and Amgen.

In which industries is Arix Bioscience primarily active?

Arix Bioscience PLC primarily operates in the biotechnology and healthcare industries.

What is the business model of Arix Bioscience?

The business model of Arix Bioscience PLC revolves around identifying and investing in innovative life science companies. Arix Bioscience PLC aims to provide long-term value to its shareholders by partnering with and supporting these companies to develop and commercialize breakthrough therapies and technologies. By leveraging its experienced team and global network, Arix Bioscience PLC seeks to unlock the full potential of these companies, driving growth and delivering impactful healthcare solutions. Through strategic investments and collaborations, Arix Bioscience PLC actively contributes to the advancement of the life sciences sector, ensuring a brighter future for patients and investors alike.

What is the P/E ratio of Arix Bioscience 2024?

The Arix Bioscience P/E ratio is 0.

What is the P/S ratio of Arix Bioscience 2024?

The Arix Bioscience P/S ratio is 0.

What is the AlleAktien quality score of Arix Bioscience?

The AlleAktien quality score for Arix Bioscience is 1/10.

What is the revenue of Arix Bioscience 2024?

The revenue cannot currently be calculated for Arix Bioscience.

How high is the profit of Arix Bioscience 2024?

The profit cannot currently be calculated for Arix Bioscience.

What is the business model of Arix Bioscience

Arix Bioscience PLC is an investment company that invests in biotechnology companies and supports them in maximizing their potential. The company's business model is based on analyzing emerging biotech companies with groundbreaking innovations and supporting their research to bring innovative products and therapies to market. Arix focuses on three main areas: science, corporate development, and fundraising. In the field of science, Arix works with brilliant scientists and researchers to develop groundbreaking innovations and new technologies and implement them into practice. The company identifies promising technologies and therapeutic approaches that have the potential to address unmet medical needs in various areas, including oncology, immunology, neurology, and metabolic diseases. Arix also offers support in corporate development to maximize the success of startups and emerging biotech companies. The company can draw on a wide range of experience and expertise to advise its portfolio companies and help them optimize their business strategies, expand their resources, and achieve their clinical and regulatory milestones. Another important area of Arix is fundraising. The company helps its portfolio companies secure funding to support the research and development of innovative products and therapies. Arix itself also invests directly in its portfolio companies to maximize their growth potential. The company leverages its extensive contacts in the biotechnology industry to develop and implement strategies for portfolio companies to accelerate growth and maximize potential for investors. Products and services offered by Arix Bioscience PLC include groundbreaking therapeutics and drugs for treating numerous diseases that have unmet needs in the medical industry. Arix invests in companies that achieve significant advances in the development of therapies and diagnostic methods focused on fighting diseases such as cancer, Alzheimer's, Parkinson's, and others. Additionally, Arix also invests in companies focused on the development of drugs and therapies for rare and genetic diseases. In summary, Arix Bioscience PLC is an innovative investment company with a strong focus on the biotechnology industry. The company has already built an impressive portfolio consisting of promising emerging biotech companies that are developing groundbreaking innovations and achieving significant progress in addressing unmet medical needs. Arix works with its portfolio companies to maximize their growth and success opportunities.

What is the Arix Bioscience dividend?

Arix Bioscience pays a dividend of 0 GBP distributed over payouts per year.

How often does Arix Bioscience pay dividends?

The dividend cannot currently be calculated for Arix Bioscience or the company does not pay out a dividend.

What is the Arix Bioscience ISIN?

The ISIN of Arix Bioscience is GB00BD045071.

What is the Arix Bioscience WKN?

The WKN of Arix Bioscience is A2DL9L.

What is the Arix Bioscience ticker?

The ticker of Arix Bioscience is ARIX.L.

How much dividend does Arix Bioscience pay?

Over the past 12 months, Arix Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arix Bioscience is expected to pay a dividend of 0 GBP.

What is the dividend yield of Arix Bioscience?

The current dividend yield of Arix Bioscience is .

When does Arix Bioscience pay dividends?

Arix Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arix Bioscience?

Arix Bioscience paid dividends every year for the past 0 years.

What is the dividend of Arix Bioscience?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arix Bioscience located?

Arix Bioscience is assigned to the 'Finance' sector.

Wann musste ich die Aktien von Arix Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arix Bioscience from 7/29/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 7/29/2024.

When did Arix Bioscience pay the last dividend?

The last dividend was paid out on 7/29/2024.

What was the dividend of Arix Bioscience in the year 2023?

In the year 2023, Arix Bioscience distributed 0 GBP as dividends.

In which currency does Arix Bioscience pay out the dividend?

The dividends of Arix Bioscience are distributed in GBP.

All fundamentals about Arix Bioscience

Our stock analysis for Arix Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arix Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.